2023 Integrated Annual Report
In 2023, we reinforced our ambition to be a leading, global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
2023 Integrated Annual Report
In 2023, we reinforced our ambition to be a leading, global mid-size biopharmaceutical company with a focus on transformative medicines in Oncology, Rare Disease and Neuroscience.
Related Reports and Accounts

2024 Universal Registration Document

2023 Universal Registration Document

Information relating to compensation elements of Mr. David Loew, CEO – 31 May 2023

Compensation policy for corporate officers Combined shareholders’ meeting of 31 May 2023

2022 Integrated Annual Report

Generation Ipsen – for positive change

Ipsen in Brief

2022 Universal Registration Document

Information relating to the compensation elements of Mr. David LOEW, Chief Executive Officer

2021 Integrated Annual Report